NCT02622906View on ClinicalTrials.gov

Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

October 31, 2015

Conditions
Angiodysplasia
Interventions
DRUG

Pasireotide

60 mg per month of the Pasireotide during 6 months

DRUG

Placebo

Vehicule injection per month during 6 months

Trial Locations (1)

75006

Société Française d'Endoscopie Digestive (SFED), Paris

All Listed Sponsors
lead

Robert Benamouzig

OTHER

NCT02622906 - Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure | Biotech Hunter | Biotech Hunter